Cargando…
KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery
We evaluated the tumor response and survival according to the KRAS oncogene status in locally advanced rectal cancer. One hundred patients with locally advanced rectal cancer (cT3-4N0-2M0) received preoperative radiation of 50.4 Gy in 28 fractions with 5-fluorouracil and total mesorectal excision. T...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616597/ https://www.ncbi.nlm.nih.gov/pubmed/26252300 http://dx.doi.org/10.1097/MD.0000000000001284 |
_version_ | 1782396670139432960 |
---|---|
author | Lee, Jeong Won Lee, Jong Hoon Shim, Byoung Yong Kim, Sung Hwan Chung, Mi-Joo Kye, Bong-Hyeon Kim, Hyung Jin Cho, Hyeon Min Jang, Hong Seok |
author_facet | Lee, Jeong Won Lee, Jong Hoon Shim, Byoung Yong Kim, Sung Hwan Chung, Mi-Joo Kye, Bong-Hyeon Kim, Hyung Jin Cho, Hyeon Min Jang, Hong Seok |
author_sort | Lee, Jeong Won |
collection | PubMed |
description | We evaluated the tumor response and survival according to the KRAS oncogene status in locally advanced rectal cancer. One hundred patients with locally advanced rectal cancer (cT3-4N0-2M0) received preoperative radiation of 50.4 Gy in 28 fractions with 5-fluorouracil and total mesorectal excision. Tumor DNA from each patient was obtained from pretreatment biopsy tissues. A Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation was found in 26 (26%) of the 100 patients. Downstaging (ypT0-2N0M0) rates after preoperative chemoradiotheray were not statistically different between the wild-type and mutant-type KRAS groups (30.8% vs 27.0%, P = 0.715, respectively). After a median follow-up time of 34 months, there was no statistically significant difference in the 3-year relapse-free survival (82.2% vs 82.6%, P = 0.512) and overall survival (94.7% vs 92.3%, P = 0.249) rates between wild-type and mutant-type KRAS groups, respectively. The KRAS mutation status does not influence the tumor response to the radiotherapy and survival in locally advanced rectal cancer patients who received preoperative chemoradiotherapy and curative surgery. |
format | Online Article Text |
id | pubmed-4616597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-46165972015-10-27 KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery Lee, Jeong Won Lee, Jong Hoon Shim, Byoung Yong Kim, Sung Hwan Chung, Mi-Joo Kye, Bong-Hyeon Kim, Hyung Jin Cho, Hyeon Min Jang, Hong Seok Medicine (Baltimore) 5700 We evaluated the tumor response and survival according to the KRAS oncogene status in locally advanced rectal cancer. One hundred patients with locally advanced rectal cancer (cT3-4N0-2M0) received preoperative radiation of 50.4 Gy in 28 fractions with 5-fluorouracil and total mesorectal excision. Tumor DNA from each patient was obtained from pretreatment biopsy tissues. A Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation was found in 26 (26%) of the 100 patients. Downstaging (ypT0-2N0M0) rates after preoperative chemoradiotheray were not statistically different between the wild-type and mutant-type KRAS groups (30.8% vs 27.0%, P = 0.715, respectively). After a median follow-up time of 34 months, there was no statistically significant difference in the 3-year relapse-free survival (82.2% vs 82.6%, P = 0.512) and overall survival (94.7% vs 92.3%, P = 0.249) rates between wild-type and mutant-type KRAS groups, respectively. The KRAS mutation status does not influence the tumor response to the radiotherapy and survival in locally advanced rectal cancer patients who received preoperative chemoradiotherapy and curative surgery. Wolters Kluwer Health 2015-08-07 /pmc/articles/PMC4616597/ /pubmed/26252300 http://dx.doi.org/10.1097/MD.0000000000001284 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5700 Lee, Jeong Won Lee, Jong Hoon Shim, Byoung Yong Kim, Sung Hwan Chung, Mi-Joo Kye, Bong-Hyeon Kim, Hyung Jin Cho, Hyeon Min Jang, Hong Seok KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery |
title | KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery |
title_full | KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery |
title_fullStr | KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery |
title_full_unstemmed | KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery |
title_short | KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery |
title_sort | kras mutation status is not a predictor for tumor response and survival in rectal cancer patients who received preoperative radiotherapy with 5-fluoropyrimidine followed by curative surgery |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616597/ https://www.ncbi.nlm.nih.gov/pubmed/26252300 http://dx.doi.org/10.1097/MD.0000000000001284 |
work_keys_str_mv | AT leejeongwon krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT leejonghoon krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT shimbyoungyong krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT kimsunghwan krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT chungmijoo krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT kyebonghyeon krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT kimhyungjin krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT chohyeonmin krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery AT janghongseok krasmutationstatusisnotapredictorfortumorresponseandsurvivalinrectalcancerpatientswhoreceivedpreoperativeradiotherapywith5fluoropyrimidinefollowedbycurativesurgery |